Activity of KBP-7072, a Novel Aminomethylcycline Antibacterial, and Tetracycline Class Comparators Against 1,057 Bacterial Pathogens Collected Worldwide During 2019

MD Huband[1], JD Thompson[1], ND Gurung[1], Qingmei Liu[2], Li Li[2], J Zhang[3], JM Streit[1], and M Castanheira[1]

[1] JMI Laboratories, North Liberty, Iowa, USA; [2] KBP Biosciences Co., Ltd., Jinan, China; [3] KBP Biosciences USA Inc., Princeton, NJ, USA

Contact Information:
Michael D. Huband, Associate Director
JMI Laboratories
345 Beaver Kreek Centre, Suite A
North Liberty, IA 52317
Phone: (319) 665-3370
Fax: (319) 665-3371
Email: michael-huband@jmilabs.com

To obtain a PDF of this poster:
- Scan the QR code
  OR
- Visit https://www.jmilabs.com/data/posters/ECCMID2021_KBP7072vRTIHAPSSSI.pdf

Charges may apply.
No personal information is stored.

Introduction

- KBP-7072 is a novel third generation aminomethylcycline antibacterial in development for the treatment of acute bacterial skin and skin structure infection (ABSSSI), community-acquired bacterial pneumonia (CABP), and complicated intra-abdominal infection (cIAI).
- KBP-7072 has completed phase I development.
- KBP-7072 has deBT.eDM0 Tc 0ott